NNNN

Anbio Biotechnology Class A Ordinary Shares

NNNN

Market cap $1.92B

Overview Fund Activity

43.68 USD

+1.13

2.66%

At close Updated Sep 16, 4:00 PM EDT

1 day

2.66%

5 days

-5.04%

1 month

-15.46%

3 months

384.79%

6 months

524.89%

Year to date

657.02%

1 year

657.02%

5 years

657.02%

10 years

657.02%

About: Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Employees: 27

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

89% more capital invested

Capital invested by funds: $496K [Q1] → $937K (+$441K) [Q2]

67% more funds holding

Funds holding: 3 [Q1] → 5 (+2) [Q2]

0.08% less ownership

Funds ownership: 0.15% [Q1] → 0.07% (-0.08%) [Q2]

See Fund Rankings

Financial journalist opinion

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

Anbio Biotechnology Announces Closing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol “NNNN.”

Anbio Biotechnology Announces Closing of Initial Public Offering

Anbio Biotechnology Announces Pricing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the pricing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (“the Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on February 19, 2025 under the ticker symbol “NNNN.”

Anbio Biotechnology Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on the calendar, some large names in the pipeline could launch in the week ahead.

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch

Anbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with significant customer concentration risks. The global IVD market is projected to grow to $119 billion by 2030, but Anbio faces stiff competition from well-established industry players.

Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch

See News Rankings

Charts implemented using Lightweight Charts™